Abstract With the promising outcomes seen in hematological malignancies, engineered T-cell therapies, notably chimeric antigen receptor (CAR) therapies, have emerged as breakthroughs in the field of oncology. Yet, their prospect in treating breast cancer and other solid tumors remains a topic of intense investigation. This presentation aims to delve into the diverse engineered T-cell treatments, contextualizing their role in breast cancer. We explore the intrinsic therapeutic challenges these modalities face and the concerted efforts in the scientific community to overcome them. We will look at the current clinical trial landscape for CAR-T cell therapies in breast cancer, underscoring their potential in shaping breast cancer treatment in the years to come. Citation Format: V. Hoyos Velez. Engineered T cell therapies- what is the outlook for breast cancer? [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr SoA1-02.